Article
The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice.
Journal of neuropathology and experimental neurology - 1 Aug 2010
Huttunen Henri J, Havas Daniel, Peach Camilla, Barren Cory, Duller Stephan, Xia Weiming, Frosch Matthew P, Hutter-Paier Birgit, Windisch Manfred, Kovacs Dora M
Abstract excerpt
Cerebral accumulation of amyloid-beta (Abeta) is characteristic of Alzheimer disease and of amyloid precursor protein (APP) transgenic mice. Here, we assessed the efficacy of CI-1011, an inhibitor of acyl-coenzyme A:cholesterol acyltransferase, which is suitable for clinical use, in reducing amyloid pathology in both young (6.5 months old) and aged (16 months old) human APP transgenic mice. Treatment of young...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.